Sartans to slow Alzheimer’s disease: A randomized double-blind, face-to-face proof-of-concept study of angiotensin receptor blockers versus ACE inhibitors in hypertensive mild-moderate AD patients using ventricular enlargement as primary outcome
University of Toronto, Sunnybrook Health Sciences Centre, University Health Network, Toronto Dementia Research Alliance, St. Michael’s Hospital,
Different classes of anti‐hypertensive drugs may have different effects on the brain beyond just blood pressure control. In this study, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), will be compared for the treatment of hypertension in patients with Alzheimer’s disease. ARBs, but not ACEIs, have been shown to both improve cognition in animal studies and interfere with disease processes involved in the development of Alzheimer’s disease. Clinical trials designed to directly compare these two anti‐hypertensive drug classes in-patients with Alzheimer’s Disease have not yet been performed.
“Our exploratory clinical study will compare ARBs versus ACEIs in a “face‐off” to slow brain degeneration in people with Alzheimer’s disease who are already taking medications to control blood pressure,” said Dr. Sandra Black, the Executive Director of the Toronto Dementia Research Alliance and Research Program Director at Sunnybrook Research Institute at the University of Toronto. “We will use brain imaging, and measure cognition and quality of life over a one year period to compare the rate of brain shrinkage in the people on ACEIs vs. ARBs.”